Skip to main content
. 2018 Aug 11;5(5):818–829. doi: 10.1002/ehf2.12341

Figure 3.

Figure 3

Impact of telbivudine on parvovirus B19 (B19V) copy number and expression in B19V‐infected UT7/EPO S1 cells. (A) Experimental design: UT7/EPO S1 cells were 24 h after plating, infected with 10 000 viral particles/cell with/out 10 ng/mL of telbivudine, and collected after 1 and 24 h for the analysis of B19V DNA copy number and mRNA expression. Bar graphs represent the mean ± SEM of (B) B19V copy number and (C) B19V cDNA, 1 and 24 h post‐B19V infection with/out telbivudine treatment in UT7/EPO S1 cells with n = 4–6/group and **P < 0.005, ***P < 0.0005, and ****P < 0.0001.